{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:37:28Z","timestamp":1782761848675,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polycystic ovary syndrome (PCOS) has significant metabolic sequelae linked to insulin resistance. This study aimed to compare clinical, metabolic, and hormonal characteristics of PCOS women with and without insulin resistance. The second aim was to compare the clinico-biochemical profiles of the various PCOS phenotypes. In this cross-sectional secondary analysis, we combined the baseline data from two separate randomized controlled trials (RCTs) in women diagnosed with PCOS. PCOS patients were categorized into the four Rotterdam PCOS phenotypes according to the presence of at least two criteria of oligomenorrhea\/anovulation (O), hyperandrogenism (H), and polycystic ovary morphology (P): O\u2013H\u2013P, H\u2013P, O\u2013H, and O\u2013P. Participants were categorized into two groups according to the homeostasis model assessment index of insulin resistance (HOMA-IR) levels:\u2009&lt;\u20093.46, and\u2009\u2265\u20093.46. The correlation between the HOMA-IR and biometric, clinical, and biochemical variables was assessed in normal weight (BMI\u2009&lt;\u200925) and overweight\/obese (BMI\u2009\u2265\u200925) PCOS women. Then, the association between PCOS phenotypes and insulin resistance was investigated using logistic regression analysis. A total of 125 PCOS patients aged 18\u201340\u00a0years were included in the present study. Based on our results, the HOMA-IR index was positively correlated with diastolic blood pressure, free androgen index, and triglycerides levels; and negatively correlated with sex hormone-binding globulin in overweight\/obese PCOS women. In addition, the HOMA-IR index was found to be positively correlated with alanine transaminase and negatively correlated with diastolic blood pressure in normal weight PCOS women. Moreover, individuals with O\u2013H\u2013P phenotype (odds ratio [OR] 2.52, 95% confidence interval [CI] 1.02\u20136.24) had about two-fold increased risk of insulin resistance. In conclusion, the full-blown PCOS (O\u2013H\u2013P) phenotype has an increased risk of insulin resistance. Accordingly, phenotype division may help physicians to predict adverse metabolic outcomes.<\/jats:p>","DOI":"10.1038\/s41598-023-37513-2","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T10:05:47Z","timestamp":1687601147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Risk factors for insulin resistance related to polycystic ovarian syndrome in Iranian population"],"prefix":"10.1038","volume":"13","author":[{"given":"Asieh","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mirahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Mohajeri-Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdieh","family":"Jamalizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedigheh","family":"Hosseinimousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooria","family":"Asili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed Mahmoud","family":"Sajjadi-Jazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,24]]},"reference":[{"key":"37513_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1210\/er.2015-1018","volume":"36","author":"DA Dumesic","year":"2015","unstructured":"Dumesic, D. A. et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr. Rev. 36, 487\u2013525. https:\/\/doi.org\/10.1210\/er.2015-1018 (2015).","journal-title":"Endocr. Rev."},{"key":"37513_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrendo.2018.24","volume":"14","author":"HF Escobar-Morreale","year":"2018","unstructured":"Escobar-Morreale, H. F. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat. Rev. Endocrinol. 14, 270\u2013284 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"37513_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4239\/wjd.v13.i3.129","volume":"13","author":"CA Amisi","year":"2022","unstructured":"Amisi, C. A. Markers of insulin resistance in polycystic ovary syndrome women: An update. World J. Diabetes 13, 129\u2013149. https:\/\/doi.org\/10.4239\/wjd.v13.i3.129 (2022).","journal-title":"World J. Diabetes"},{"key":"37513_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1210\/er.2011-1034","volume":"33","author":"E Diamanti-Kandarakis","year":"2012","unstructured":"Diamanti-Kandarakis, E. & Dunaif, A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr. Rev. 33, 981\u20131030 (2012).","journal-title":"Endocr. Rev."},{"key":"37513_CR5","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/humrep\/dey256","volume":"33","author":"HJ Teede","year":"2018","unstructured":"Teede, H. J. et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum. Reprod. 33, 1602\u20131618. https:\/\/doi.org\/10.1093\/humrep\/dey256 (2018).","journal-title":"Hum. Reprod."},{"key":"37513_CR6","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.fertnstert.2014.08.001","volume":"102","author":"NM Daan","year":"2014","unstructured":"Daan, N. M. et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: Who is really at risk?. Fertil. Steril. 102, 1444\u20131451 (2014).","journal-title":"Fertil. Steril."},{"key":"37513_CR7","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1093\/humrep\/der088","volume":"26","author":"MC Amato","year":"2011","unstructured":"Amato, M. C., Verghi, M., Galluzzo, A. & Giordano, C. The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: A likely condition of cardiometabolic risk. Hum. Reprod. 26, 1486\u20131494 (2011).","journal-title":"Hum. Reprod."},{"issue":"670","key":"37513_CR8","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1016\/j.ajog.2008.01.037","volume":"198","author":"RP Kauffman","year":"2008","unstructured":"Kauffman, R. P., Baker, T. E., Baker, V. M., DiMarino, P. & Castracane, V. D. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am. J. Obstet. Gynecol. 198(670), e671-677. https:\/\/doi.org\/10.1016\/j.ajog.2008.01.037 (2008) (Discussion 670.e677\u2013610).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"37513_CR9","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3109\/09513590.2013.819082","volume":"29","author":"S Ates","year":"2013","unstructured":"Ates, S. et al. Different phenotypes of polycystic ovary syndrome in Turkish women: Clinical and endocrine characteristics. Gynecol. Endocrinol. 29, 931\u2013935 (2013).","journal-title":"Gynecol. Endocrinol."},{"key":"37513_CR10","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1016\/j.clnu.2021.02.004","volume":"40","author":"A Mansour","year":"2021","unstructured":"Mansour, A. et al. Effect of resveratrol on menstrual cyclicity, hyperandrogenism and metabolic profile in women with PCOS. Clin. Nutr. 40, 4106\u20134112 (2021).","journal-title":"Clin. Nutr."},{"key":"37513_CR11","doi-asserted-by":"publisher","first-page":"590392","DOI":"10.3389\/fendo.2020.590392","volume":"11","author":"M Qorbani","year":"2020","unstructured":"Qorbani, M. et al. The effect of oligopin supplementation on hormonal and metabolic profiles in the polycystic ovary syndrome: A randomized controlled trial. Front. Endocrinol. 11, 590392. https:\/\/doi.org\/10.3389\/fendo.2020.590392 (2020).","journal-title":"Front. Endocrinol."},{"key":"37513_CR12","doi-asserted-by":"publisher","unstructured":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41\u201347. https:\/\/doi.org\/10.1093\/humrep\/deh098 (2004).","DOI":"10.1093\/humrep\/deh098"},{"key":"37513_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5603\/KP.2019.0018","volume":"77","author":"B Williams","year":"2019","unstructured":"Williams, B. et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Kardiol. Polska (Polish Heart J.) 77, 71\u2013159 (2019).","journal-title":"Kardiol. Polska (Polish Heart J.)"},{"key":"37513_CR14","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/s0015-0282(00)00501-x","volume":"73","author":"B Kolodziejczyk","year":"2000","unstructured":"Kolodziejczyk, B., Duleba, A. J., Spaczynski, R. Z. & Pawelczyk, L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil. Steril. 73, 1149\u20131154. https:\/\/doi.org\/10.1016\/s0015-0282(00)00501-x (2000).","journal-title":"Fertil. Steril."},{"key":"37513_CR15","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/0002-9378(81)90746-8","volume":"140","author":"R Hatch","year":"1981","unstructured":"Hatch, R., Rosenfield, R. L., Kim, M. H. & Tredway, D. Hirsutism: Implications, etiology, and management. Am. J. Obstet. Gynecol. 140, 815\u2013830. https:\/\/doi.org\/10.1016\/0002-9378(81)90746-8 (1981).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"37513_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.5001\/omj.2012.112","volume":"27","author":"MK Al Kindi","year":"2012","unstructured":"Al Kindi, M. K., Al Essry, F. S., Al Essry, F. S. & Mula-Abed, W.-A.S. Validity of serum testosterone, free androgen index, and calculated free testosterone in women with suspected hyperandrogenism. Oman Med. J. 27, 471 (2012).","journal-title":"Oman Med. J."},{"key":"37513_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/bf00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews, D. R. et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412\u2013419. https:\/\/doi.org\/10.1007\/bf00280883 (1985).","journal-title":"Diabetologia"},{"key":"37513_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6823-13-47","volume":"13","author":"P Gayoso-Diz","year":"2013","unstructured":"Gayoso-Diz, P. et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: Effect of gender and age: EPIRCE cross-sectional study. BMC Endocr. Disord. 13, 1\u201310 (2013).","journal-title":"BMC Endocr. Disord."},{"key":"37513_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.20945\/2359-3997000000442","volume":"66","author":"P Kabakchieva","year":"2022","unstructured":"Kabakchieva, P. et al. Elevated levels of interleukin-18 are associated with several indices of general and visceral adiposity and insulin resistance in women with polycystic ovary syndrome. Arch. Endocrinol. Metab. 66, 3\u201311. https:\/\/doi.org\/10.20945\/2359-3997000000442 (2022).","journal-title":"Arch. Endocrinol. Metab."},{"key":"37513_CR20","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.1210\/jc.2005-0694","volume":"90","author":"F Gonz\u00e1lez","year":"2005","unstructured":"Gonz\u00e1lez, F., Minium, J., Rote, N. S. & Kirwan, J. P. Hyperglycemia alters tumor necrosis factor-alpha release from mononuclear cells in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 5336\u20135342. https:\/\/doi.org\/10.1210\/jc.2005-0694 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"37513_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2119\/2007-00119.Tilg","volume":"14","author":"H Tilg","year":"2008","unstructured":"Tilg, H. & Moschen, A. R. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med. 14, 222\u2013231 (2008).","journal-title":"Mol. Med."},{"key":"37513_CR22","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.3390\/ijms22052734","volume":"22","author":"S Aboeldalyl","year":"2021","unstructured":"Aboeldalyl, S. et al. The role of chronic inflammation in polycystic ovarian syndrome: A systematic review and meta-analysis. Int. J. Mol. Sci. 22, 2734 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"37513_CR23","doi-asserted-by":"publisher","first-page":"103628","DOI":"10.1016\/j.jri.2022.103628","volume":"151","author":"Y Zhai","year":"2022","unstructured":"Zhai, Y. & Pang, Y. Systemic and ovarian inflammation in women with polycystic ovary syndrome. J. Reprod. Immunol. 151, 103628. https:\/\/doi.org\/10.1016\/j.jri.2022.103628 (2022).","journal-title":"J. Reprod. Immunol."},{"key":"37513_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jpag.2013.09.015","volume":"27","author":"G Stabile","year":"2014","unstructured":"Stabile, G. et al. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. J. Pediatr. Adolesc. Gynecol. 27, 177\u2013182 (2014).","journal-title":"J. Pediatr. Adolesc. Gynecol."},{"key":"37513_CR25","doi-asserted-by":"publisher","first-page":"8183","DOI":"10.1097\/MD.0000000000008183","volume":"96","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: A meta-analysis: a PRISMA-compliant article. Medicine 96, 8183 (2017).","journal-title":"Medicine"},{"key":"37513_CR26","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2021.210310","author":"A Khichar","year":"2021","unstructured":"Khichar, A., Gupta, S., Mishra, S. & Meena, M. Assessment of inflammatory markers in women with PCOS and their correlation with insulin resistance. Clin. Lab. https:\/\/doi.org\/10.7754\/Clin.Lab.2021.210310 (2021).","journal-title":"Clin. Lab."},{"key":"37513_CR27","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.3390\/ijms22073789","volume":"22","author":"E Rudnicka","year":"2021","unstructured":"Rudnicka, E. et al. Chronic low grade inflammation in pathogenesis of PCOS. Int. J. Mol. Sci. 22, 3789 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"37513_CR28","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1056\/NEJMoa0804381","volume":"361","author":"EL Ding","year":"2009","unstructured":"Ding, E. L. et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N. Engl. J. Med. 361, 1152\u20131163 (2009).","journal-title":"N. Engl. J. Med."},{"key":"37513_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2261-13-30","volume":"13","author":"B Daka","year":"2013","unstructured":"Daka, B. et al. Low sex hormone-binding globulin is associated with hypertension: A cross-sectional study in a Swedish population. BMC Cardiovasc. Disord. 13, 1\u20138 (2013).","journal-title":"BMC Cardiovasc. Disord."},{"key":"37513_CR30","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.2337\/dc09-1788","volume":"33","author":"C Li","year":"2010","unstructured":"Li, C., Ford, E. S., Li, B., Giles, W. H. & Liu, S. Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabetes Care 33, 1618\u20131624 (2010).","journal-title":"Diabetes Care"},{"key":"37513_CR31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s42000-020-00219-5","volume":"19","author":"C Fu","year":"2020","unstructured":"Fu, C. et al. Efficacy of sex hormone-binding globulin on predicting metabolic syndrome in newly diagnosed and untreated patients with polycystic ovary syndrome. Hormones 19, 439\u2013445. https:\/\/doi.org\/10.1007\/s42000-020-00219-5 (2020).","journal-title":"Hormones"},{"key":"37513_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cca.2019.09.010","volume":"499","author":"J-L Zhu","year":"2019","unstructured":"Zhu, J.-L., Chen, Z., Feng, W.-J., Long, S.-L. & Mo, Z.-C. Sex hormone-binding globulin and polycystic ovary syndrome. Clin. Chim. Acta 499, 142\u2013148. https:\/\/doi.org\/10.1016\/j.cca.2019.09.010 (2019).","journal-title":"Clin. Chim. Acta"},{"key":"37513_CR33","first-page":"1","volume":"2020","author":"X Luo","year":"2020","unstructured":"Luo, X. et al. Decreased sex hormone-binding globulin indicated worse biometric, lipid, liver, and renal function parameters in women with polycystic ovary syndrome. Int. J. Endocrinol. 2020, 1\u201310 (2020).","journal-title":"Int. J. Endocrinol."},{"key":"37513_CR34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s12020-016-0958-x","volume":"55","author":"R Mioni","year":"2017","unstructured":"Mioni, R. et al. Hyperinsulinemia and obese phenotype differently influence blood pressure in young normotensive patients with polycystic ovary syndrome. Endocrine 55, 625\u2013634 (2017).","journal-title":"Endocrine"},{"key":"37513_CR35","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1007\/s43032-021-00535-0","volume":"28","author":"F Chen","year":"2021","unstructured":"Chen, F. et al. Evaluation of the efficacy of sex hormone-binding globulin in insulin resistance assessment based on HOMA-IR in patients with PCOS. Reprod. Sci. 28, 2504\u20132513 (2021).","journal-title":"Reprod. Sci."},{"key":"37513_CR36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.29252\/ijrm.14.4.263","volume":"14","author":"P Layegh","year":"2016","unstructured":"Layegh, P., Mousavi, Z., Tehrani, D. F., Parizadeh, S. M. R. & Khajedaluee, M. Insulin resistance and endocrine-metabolic abnormalities in polycystic ovarian syndrome: Comparison between obese and non-obese PCOS patients. Int. J. Reprod. Biomed. 14, 263 (2016).","journal-title":"Int. J. Reprod. Biomed."},{"key":"37513_CR37","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1590\/S0004-27302007000700013","volume":"51","author":"CR Barcellos","year":"2007","unstructured":"Barcellos, C. R. et al. Impact of body mass index on blood pressure levels in patients with polycystic ovary syndrome. Arq. Bras. Endocrinol. Metabol. 51, 1104\u20131109 (2007).","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"37513_CR38","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.fertnstert.2004.08.020","volume":"83","author":"JB Schwimmer","year":"2005","unstructured":"Schwimmer, J. B., Khorram, O., Chiu, V. & Schwimmer, W. B. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil. Steril. 83, 494\u2013497 (2005).","journal-title":"Fertil. Steril."},{"key":"37513_CR39","doi-asserted-by":"publisher","first-page":"8351","DOI":"10.3748\/wjg.v20.i26.8351","volume":"20","author":"E Vassilatou","year":"2014","unstructured":"Vassilatou, E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J. Gastroenterol 20, 8351\u20138363. https:\/\/doi.org\/10.3748\/wjg.v20.i26.8351 (2014).","journal-title":"World J. Gastroenterol"},{"key":"37513_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030856","author":"R Manzano-Nunez","year":"2023","unstructured":"Manzano-Nunez, R. et al. Non-alcoholic fatty liver disease in patients with polycystic ovary syndrome: A systematic review, meta-analysis, and meta-regression. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm12030856 (2023).","journal-title":"J. Clin. Med."},{"key":"37513_CR41","first-page":"4259","volume":"15","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. Analyses of risk factors for polycystic ovary syndrome complicated with non-alcoholic fatty liver disease. Exp. Ther. Med. 15, 4259\u20134264 (2018).","journal-title":"Exp. Ther. Med."},{"key":"37513_CR42","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s43032-022-01030-w","volume":"30","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. The associations between alanine aminotransferase and other biochemical parameters in lean PCOS. Reprod. Sci. 30, 633\u2013641. https:\/\/doi.org\/10.1007\/s43032-022-01030-w (2023).","journal-title":"Reprod. Sci."},{"key":"37513_CR43","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/j.1365-2036.2011.04579.x","volume":"33","author":"A Baranova","year":"2011","unstructured":"Baranova, A., Tran, T. P., Birerdinc, A. & Younossi, Z. M. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 33, 801\u2013814. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04579.x (2011).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"37513_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3464","volume":"38","author":"A Krentowska","year":"2022","unstructured":"Krentowska, A. & Kowalska, I. Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome. Diabetes Metab. Res. Rev. 38, e3464 (2022).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"37513_CR45","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/cen.14063","volume":"91","author":"E Carmina","year":"2019","unstructured":"Carmina, E., Nasrallah, M. P., Guastella, E. & Lobo, R. A. Characterization of metabolic changes in the phenotypes of women with polycystic ovary syndrome in a large Mediterranean population from Sicily. Clin. Endocrinol. 91, 553\u2013560. https:\/\/doi.org\/10.1111\/cen.14063 (2019).","journal-title":"Clin. Endocrinol."},{"key":"37513_CR46","doi-asserted-by":"publisher","first-page":"e0167036","DOI":"10.1371\/journal.pone.0167036","volume":"11","author":"H Li","year":"2016","unstructured":"Li, H. et al. Should all women with polycystic ovary syndrome be screened for metabolic parameters?: A hospital-based observational study. PLoS ONE 11, e0167036. https:\/\/doi.org\/10.1371\/journal.pone.0167036 (2016).","journal-title":"PLoS ONE"},{"key":"37513_CR47","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/jcm9030732","volume":"9","author":"AM Polak","year":"2020","unstructured":"Polak, A. M. et al. Body composition, serum concentrations of androgens and insulin resistance in different polycystic ovary syndrome phenotypes. J. Clin. Med. 9, 732 (2020).","journal-title":"J. Clin. Med."},{"key":"37513_CR48","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3109\/09513590.2011.633658","volume":"28","author":"E Ozkaya","year":"2012","unstructured":"Ozkaya, E. et al. Is hyperandrogenemia protective for fibrocystic breast disease in PCOS?. Gynecol. Endocrinol. 28, 468\u2013471 (2012).","journal-title":"Gynecol. Endocrinol."},{"key":"37513_CR49","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s12020-011-9437-6","volume":"39","author":"B Dilbaz","year":"2011","unstructured":"Dilbaz, B., \u00d6zkaya, E., Cinar, M., Cakir, E. & Dilbaz, S. Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. Endocrine 39, 272\u2013277 (2011).","journal-title":"Endocrine"},{"key":"37513_CR50","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/cen.12406","volume":"81","author":"F Hosseinpanah","year":"2014","unstructured":"Hosseinpanah, F., Barzin, M., Keihani, S., Ramezani Tehrani, F. & Azizi, F. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS prevalence study. Clin. Endocrinol. 81, 93\u201399 (2014).","journal-title":"Clin. Endocrinol."},{"key":"37513_CR51","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1080\/09513590.2019.1613640","volume":"35","author":"M Gupta","year":"2019","unstructured":"Gupta, M. et al. Correlation of body mass index (BMI), anti-mullerian hormone (AMH), and insulin resistance among different polycystic ovary syndrome (PCOS) phenotypes: A cross-sectional study. Gynecol. Endocrinol. 35, 970\u2013973. https:\/\/doi.org\/10.1080\/09513590.2019.1613640 (2019).","journal-title":"Gynecol. Endocrinol."},{"key":"37513_CR52","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4103\/ijem.IJEM_30_19","volume":"23","author":"G Sachdeva","year":"2019","unstructured":"Sachdeva, G., Gainder, S., Suri, V., Sachdeva, N. & Chopra, S. Comparison of the different PCOS phenotypes based on clinical metabolic, and hormonal profile, and their response to clomiphene. Indian J. Endocrinol. Metab. 23, 326\u2013331. https:\/\/doi.org\/10.4103\/ijem.IJEM_30_19 (2019).","journal-title":"Indian J. Endocrinol. Metab."},{"key":"37513_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12902-021-00710-z","volume":"21","author":"FKH Shirazi","year":"2021","unstructured":"Shirazi, F. K. H., Khodamoradi, Z. & Jeddi, M. Insulin resistance and high molecular weight adiponectin in obese and non-obese patients with polycystic ovarian syndrome (PCOS). BMC Endocr. Disord. 21, 45. https:\/\/doi.org\/10.1186\/s12902-021-00710-z (2021).","journal-title":"BMC Endocr. Disord."},{"key":"37513_CR54","doi-asserted-by":"publisher","first-page":"E628","DOI":"10.1210\/jc.2012-3908","volume":"98","author":"P Moghetti","year":"2013","unstructured":"Moghetti, P. et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 98, E628\u2013E637 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"37513_CR55","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1038\/s41598-017-05717-y","volume":"7","author":"M Al-Jefout","year":"2017","unstructured":"Al-Jefout, M., Alnawaiseh, N. & Al-Qtaitat, A. Insulin resistance and obesity among infertile women with different polycystic ovary syndrome phenotypes. Sci. Rep. 7, 5339. https:\/\/doi.org\/10.1038\/s41598-017-05717-y (2017).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37513-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37513-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37513-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T16:04:31Z","timestamp":1702656271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37513-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,24]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["37513"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-37513-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,24]]},"assertion":[{"value":"15 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10269"}}